174 related articles for article (PubMed ID: 37916156)
1. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Gallagher L; Xiao J; Hsueh J; Shah S; Danner M; Zwart A; Ayoob M; Yung T; Simpson T; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; Collins SP
Front Oncol; 2023; 13():1289249. PubMed ID: 37916156
[TBL] [Abstract][Full Text] [Related]
2. Impact of neoadjuvant relugolix on patient-reported sexual function and bother.
Hsueh JY; Gallagher L; Koh MJ; Eden S; Shah S; Wells M; Danner M; Zwart A; Ayoob M; Kumar D; Leger P; Dawson NA; Suy S; Rubin R; Collins SP
Front Oncol; 2024; 14():1377103. PubMed ID: 38665954
[TBL] [Abstract][Full Text] [Related]
3. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
Kataria S; Koneru H; Guleria S; Danner M; Ayoob M; Yung T; Lei S; Collins BT; Suy S; Lynch JH; Kole T; Collins SP
Front Oncol; 2017; 7():157. PubMed ID: 28791252
[TBL] [Abstract][Full Text] [Related]
6. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
Shah S; Pepin A; Jatar S; Hsueh J; Gallagher L; Danner MT; Zwart A; Ayoob M; Yung TM; Kumar D; Aghdam N; Leger PD; Dawson NA; Simeng S; Collins SP
Cureus; 2024 Mar; 16(3):e55729. PubMed ID: 38586683
[TBL] [Abstract][Full Text] [Related]
7. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Spratt DE; George DJ; Shore ND; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown BA; Lu S; Fallick M; Hanson S; Tombal BF
JAMA Oncol; 2024 May; 10(5):594-602. PubMed ID: 38451492
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
10. Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT).
Shah S; Pepin A; Forsthoefel M; Burlile J; Collins BT; Simeng S; Aghdam N; Collins S
Cureus; 2023 Aug; 15(8):e44440. PubMed ID: 37791195
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
12. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
Kim HJ; Phak JH; Kim WC
Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
Phak JH; Kim HJ; Kim WC
Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
[TBL] [Abstract][Full Text] [Related]
15. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
16. Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer.
Aghdam N; Pepin AN; Creswell M; Hsieh K; Smith C; Drescher N; Danner M; Ayoob M; Yung T; Lei S; Kumar D; Collins BT; Lischalk JW; Krishnan P; Suy S; Lynch J; Bandi G; Hankins RA; Collins SP
Front Oncol; 2020; 10():551491. PubMed ID: 33251131
[No Abstract] [Full Text] [Related]
17. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
19. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]